Trade Abbvie - ABBV CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.18 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026346% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.004124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Abbvie Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 144.51 |
| Open* | 144.93 |
| 1-Year Change* | -11.52% |
| Day's Range* | 144.93 - 146.91 |
| 52 wk Range | 130.96-168.11 |
| Average Volume (10 days) | 5.91M |
| Average Volume (3 months) | 101.56M |
| Market Cap | 244.93B |
| P/E Ratio | 38.06 |
| Shares Outstanding | 1.77B |
| Revenue | 55.14B |
| EPS | 3.65 |
| Dividend (Yield %) | 4.46911 |
| Beta | 0.44 |
| Next Earnings Date | Feb 7, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 6, 2023 | 146.35 | 1.78 | 1.23% | 144.57 | 147.01 | 144.56 |
| Dec 5, 2023 | 144.51 | 0.72 | 0.50% | 143.79 | 145.03 | 142.53 |
| Dec 4, 2023 | 144.06 | 0.80 | 0.56% | 143.26 | 145.43 | 143.22 |
| Dec 1, 2023 | 143.31 | 0.99 | 0.70% | 142.32 | 144.00 | 141.84 |
| Nov 30, 2023 | 142.33 | 4.38 | 3.18% | 137.95 | 142.63 | 137.52 |
| Nov 29, 2023 | 138.44 | 0.48 | 0.35% | 137.96 | 139.02 | 137.59 |
| Nov 28, 2023 | 137.99 | -0.47 | -0.34% | 138.46 | 139.57 | 137.81 |
| Nov 27, 2023 | 139.00 | 0.54 | 0.39% | 138.46 | 139.31 | 137.54 |
| Nov 24, 2023 | 138.63 | -0.73 | -0.52% | 139.36 | 139.88 | 138.39 |
| Nov 22, 2023 | 138.31 | -0.51 | -0.37% | 138.82 | 139.69 | 137.96 |
| Nov 21, 2023 | 138.66 | 0.20 | 0.14% | 138.46 | 139.30 | 137.68 |
| Nov 20, 2023 | 138.29 | 1.32 | 0.96% | 136.97 | 138.60 | 136.96 |
| Nov 17, 2023 | 138.21 | 0.25 | 0.18% | 137.96 | 138.79 | 137.07 |
| Nov 16, 2023 | 138.22 | 0.71 | 0.52% | 137.51 | 138.75 | 136.98 |
| Nov 15, 2023 | 137.48 | -0.47 | -0.34% | 137.95 | 138.07 | 135.96 |
| Nov 14, 2023 | 138.00 | -0.60 | -0.43% | 138.60 | 140.03 | 137.77 |
| Nov 13, 2023 | 138.57 | 0.02 | 0.01% | 138.55 | 139.08 | 137.17 |
| Nov 10, 2023 | 138.55 | 0.40 | 0.29% | 138.15 | 139.24 | 136.35 |
| Nov 9, 2023 | 137.97 | -2.82 | -2.00% | 140.79 | 140.85 | 135.79 |
| Nov 8, 2023 | 141.94 | -1.23 | -0.86% | 143.17 | 143.60 | 141.85 |
Abbvie Events
| Time (UTC) | Country | Event |
|---|---|---|
| Friday, January 12, 2024 | ||
| Time (UTC) 12:00 | Country US
| Event Abbvie Inc Abbvie IncForecast -Previous - |
| Monday, January 15, 2024 | ||
| Time (UTC) 12:00 | Country US
| Event Abbvie Inc Abbvie IncForecast -Previous - |
| Time (UTC) 12:00 | Country US
| Event Abbvie Inc Abbvie IncForecast -Previous - |
| Wednesday, February 7, 2024 | ||
| Time (UTC) 14:30 | Country US
| Event Q4 2023 Abbvie Inc Earnings Release Q4 2023 Abbvie Inc Earnings ReleaseForecast -Previous - |
| Thursday, April 25, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q1 2024 Abbvie Inc Earnings Release Q1 2024 Abbvie Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 58054 | 56197 | 45804 | 33266 | 32753 |
| Revenue | 58054 | 56197 | 45804 | 33266 | 32753 |
| Cost of Revenue, Total | 16527 | 17314 | 15257 | 7606 | 7557 |
| Gross Profit | 41527 | 38883 | 30547 | 25660 | 25196 |
| Total Operating Expense | 39937 | 38273 | 34441 | 20283 | 26370 |
| Selling/General/Admin. Expenses, Total | 14861 | 11996 | 11299 | 6942 | 7399 |
| Research & Development | 6487 | 6982 | 6181 | 5407 | 5229 |
| Interest Expense (Income) - Net Operating | -167 | 161 | |||
| Unusual Expense (Income) | 2006 | 1549 | 1704 | 505 | 5524 |
| Other Operating Expenses, Total | 56 | 432 | 0 | -10 | 500 |
| Operating Income | 18117 | 17924 | 11363 | 12983 | 6383 |
| Interest Income (Expense), Net Non-Operating | -2192 | -2435 | -2351 | -1551 | -1168 |
| Other, Net | -2448 | -2500 | -5614 | -3006 | -18 |
| Net Income Before Taxes | 13477 | 12989 | 3398 | 8426 | 5197 |
| Net Income After Taxes | 11845 | 11549 | 4622 | 7882 | 5773 |
| Net Income Before Extra. Items | 11836 | 11542 | 4616 | 7882 | 5773 |
| Net Income | 11836 | 11542 | 4616 | 7882 | 5687 |
| Total Adjustments to Net Income | -54 | -74 | -60 | -40 | -30 |
| Income Available to Common Excl. Extra. Items | 11782 | 11468 | 4556 | 7842 | 5743 |
| Income Available to Common Incl. Extra. Items | 11782 | 11468 | 4556 | 7842 | 5657 |
| Diluted Net Income | 11782 | 11468 | 4556 | 7842 | 5657 |
| Diluted Weighted Average Shares | 1778 | 1777 | 1673 | 1484 | 1546 |
| Diluted EPS Excluding Extraordinary Items | 6.62655 | 6.45357 | 2.72325 | 5.28437 | 3.71475 |
| Dividends per Share - Common Stock Primary Issue | 5.64 | 5.2 | 4.72 | 4.28 | 3.59 |
| Diluted Normalized EPS | 7.78476 | 7.31817 | 3.65923 | 5.75749 | 6.27662 |
| Total Extraordinary Items | -86 | ||||
| Minority Interest | -9 | -7 | -6 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total revenue | 13927 | 13865 | 12225 | 15121 | 14812 |
| Revenue | 13927 | 13865 | 12225 | 15121 | 14812 |
| Cost of Revenue, Total | 6467 | 4208 | 3972 | 4134 | 4228 |
| Gross Profit | 7460 | 9657 | 8253 | 10987 | 10584 |
| Total Operating Expense | 11646 | 9352 | 9457 | 9619 | 10209 |
| Selling/General/Admin. Expenses, Total | 3332 | 3217 | 2995 | 3252 | 3216 |
| Research & Development | 1721 | 1732 | 1662 | 1781 | 1610 |
| Unusual Expense (Income) | 126 | 364 | 838 | 453 | 926 |
| Other Operating Expenses, Total | 0 | -169 | -10 | -1 | 229 |
| Operating Income | 2281 | 4513 | 2768 | 5502 | 4603 |
| Interest Income (Expense), Net Non-Operating | -423 | -491 | -489 | -516 | -533 |
| Other, Net | 95 | -1412 | -1804 | -2021 | 330 |
| Net Income Before Taxes | 1953 | 2610 | 475 | 2965 | 4400 |
| Net Income After Taxes | 1781 | 2027 | 241 | 2472 | 3952 |
| Minority Interest | -3 | -3 | -2 | 1 | -3 |
| Net Income Before Extra. Items | 1778 | 2024 | 239 | 2473 | 3949 |
| Net Income | 1778 | 2024 | 239 | 2473 | 3949 |
| Total Adjustments to Net Income | -11 | -11 | -11 | -18 | |
| Income Available to Common Excl. Extra. Items | 1778 | 2013 | 228 | 2462 | 3931 |
| Income Available to Common Incl. Extra. Items | 1778 | 2013 | 228 | 2462 | 3931 |
| Diluted Net Income | 1778 | 2013 | 228 | 2462 | 3931 |
| Diluted Weighted Average Shares | 1771 | 1771 | 1776 | 1781 | 1776 |
| Diluted EPS Excluding Extraordinary Items | 1.00395 | 1.13665 | 0.12838 | 1.38237 | 2.2134 |
| Dividends per Share - Common Stock Primary Issue | 1.48 | 1.48 | 1.48 | 1.41 | 1.41 |
| Diluted Normalized EPS | 1.07212 | 1.33948 | 0.4171 | 1.66299 | 2.70929 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 28463 | 27928 | 24173 | 49519 | 16945 |
| Cash and Short Term Investments | 9229 | 9830 | 8479 | 39924 | 8061 |
| Cash & Equivalents | 9201 | 9746 | 8449 | 39924 | 7289 |
| Short Term Investments | 28 | 84 | 30 | 0 | 772 |
| Total Receivables, Net | 11254 | 9977 | 8822 | 5428 | 5384 |
| Accounts Receivable - Trade, Net | 11254 | 9977 | 8822 | 5428 | 5384 |
| Total Inventory | 3579 | 3128 | 3310 | 1813 | 1605 |
| Prepaid Expenses | 4401 | 4993 | 3562 | 2332 | 1763 |
| Other Current Assets, Total | 22 | 132 | |||
| Total Assets | 138805 | 146529 | 150565 | 89115 | 59352 |
| Property/Plant/Equipment, Total - Net | 5672 | 5872 | 6143 | 3306 | 2883 |
| Property/Plant/Equipment, Total - Gross | 11723 | 11489 | 11754 | 8532 | 8396 |
| Accumulated Depreciation, Total | -6051 | -5617 | -5611 | -5226 | -5513 |
| Goodwill, Net | 32156 | 32379 | 33124 | 15604 | 15663 |
| Intangibles, Net | 67439 | 75951 | 82876 | 18649 | 21233 |
| Long Term Investments | 241 | 277 | 293 | 93 | 1420 |
| Other Long Term Assets, Total | 4834 | 4122 | 3956 | 1944 | 1208 |
| Total Current Liabilities | 29538 | 35194 | 28661 | 15585 | 17239 |
| Accounts Payable | 2934 | 2882 | 2276 | 1452 | 1546 |
| Payable/Accrued | 6065 | 7057 | 6516 | 3128 | 4026 |
| Accrued Expenses | 12254 | 10217 | 9032 | 5423 | 4726 |
| Notes Payable/Short Term Debt | 1 | 14 | 34 | 0 | 3699 |
| Current Port. of LT Debt/Capital Leases | 4135 | 12481 | 8468 | 3753 | 1609 |
| Other Current Liabilities, Total | 4149 | 2543 | 2335 | 1829 | 1633 |
| Total Liabilities | 121551 | 131121 | 137489 | 97287 | 67798 |
| Total Long Term Debt | 59135 | 64189 | 77554 | 62975 | 35002 |
| Long Term Debt | 59118 | 64164 | 77533 | 62955 | 35002 |
| Deferred Income Tax | 2190 | 3009 | 3646 | 1130 | 1067 |
| Other Liabilities, Total | 30655 | 28701 | 27607 | 17597 | 14490 |
| Total Equity | 17254 | 15408 | 13076 | -8172 | -8446 |
| Common Stock | 18 | 18 | 18 | 18 | 18 |
| Additional Paid-In Capital | 19245 | 18305 | 17384 | 15193 | 14756 |
| Retained Earnings (Accumulated Deficit) | 4784 | 3127 | 1055 | 4717 | 3368 |
| Treasury Stock - Common | -4594 | -3143 | -2264 | -24504 | -24108 |
| Unrealized Gain (Loss) | 0 | 0 | -10 | ||
| Other Equity, Total | -2199 | -2899 | -3117 | -3596 | -2470 |
| Total Liabilities & Shareholders’ Equity | 138805 | 146529 | 150565 | 89115 | 59352 |
| Total Common Shares Outstanding | 1769.18 | 1768.34 | 1765.13 | 1478.91 | 1478.82 |
| Capital Lease Obligations | 17 | 25 | 21 | 20 | |
| Minority Interest | 33 | 28 | 21 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 33224 | 28852 | 26488 | 28463 | 30364 |
| Cash and Short Term Investments | 13290 | 8766 | 6722 | 9229 | 11879 |
| Cash & Equivalents | 13287 | 8759 | 6711 | 9201 | 11832 |
| Short Term Investments | 3 | 7 | 11 | 28 | 47 |
| Total Receivables, Net | 11412 | 11491 | 11473 | 11254 | 10743 |
| Accounts Receivable - Trade, Net | 11412 | 11491 | 11473 | 11254 | 10743 |
| Total Inventory | 3981 | 4055 | 3833 | 3579 | 3172 |
| Prepaid Expenses | 4541 | 4540 | 4460 | 4401 | 4570 |
| Total Assets | 136221 | 135367 | 134544 | 138805 | 141325 |
| Property/Plant/Equipment, Total - Net | 4934 | 4943 | 4931 | 4935 | 4893 |
| Property/Plant/Equipment, Total - Gross | 11374 | 11318 | 11142 | 10986 | 10679 |
| Accumulated Depreciation, Total | -6440 | -6375 | -6211 | -6051 | -5786 |
| Goodwill, Net | 32091 | 32224 | 32220 | 32156 | 31726 |
| Intangibles, Net | 58603 | 62862 | 64848 | 67439 | 68725 |
| Long Term Investments | 275 | 288 | 257 | 241 | 235 |
| Other Long Term Assets, Total | 7094 | 6198 | 5800 | 5571 | 5382 |
| Total Current Liabilities | 34773 | 32239 | 27590 | 29538 | 32712 |
| Payable/Accrued | 29658 | 27036 | 24789 | 25402 | 23505 |
| Notes Payable/Short Term Debt | 2 | 0 | 1 | 1 | 10 |
| Current Port. of LT Debt/Capital Leases | 5113 | 5203 | 2800 | 4135 | 9197 |
| Total Liabilities | 124127 | 122501 | 121270 | 121551 | 125331 |
| Total Long Term Debt | 55631 | 55812 | 59292 | 59135 | 60399 |
| Long Term Debt | 55631 | 55812 | 59292 | 59135 | 60399 |
| Deferred Income Tax | 2044 | 2124 | 2110 | 2190 | 1972 |
| Minority Interest | 35 | 32 | 29 | 33 | 33 |
| Other Liabilities, Total | 31644 | 32294 | 32249 | 30655 | 30215 |
| Total Equity | 12094 | 12866 | 13274 | 17254 | 15994 |
| Common Stock | 18 | 18 | 18 | 18 | 18 |
| Additional Paid-In Capital | 20021 | 19839 | 19619 | 19245 | 19056 |
| Retained Earnings (Accumulated Deficit) | 933 | 1789 | 2393 | 4784 | 4953 |
| Treasury Stock - Common | -6525 | -6528 | -6524 | -4594 | -4590 |
| Other Equity, Total | -2353 | -2252 | -2232 | -2199 | -3443 |
| Total Liabilities & Shareholders’ Equity | 136221 | 135367 | 134544 | 138805 | 141325 |
| Total Common Shares Outstanding | 1765.49 | 1764.8 | 1763.97 | 1769.18 | 1768.4 |
| Capital Lease Obligations |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 11845 | 11549 | 4622 | 7882 | 5687 |
| Cash From Operating Activities | 24943 | 22777 | 17588 | 13324 | 13427 |
| Cash From Operating Activities | 778 | 803 | 666 | 464 | 471 |
| Amortization | 7689 | 7718 | 5805 | 1553 | 1294 |
| Non-Cash Items | 6820 | 4927 | 8714 | 4754 | 7101 |
| Cash Taxes Paid | 2988 | 3648 | 1674 | 1447 | 35 |
| Cash Interest Paid | 2546 | 2712 | 2619 | 1794 | 1215 |
| Changes in Working Capital | -258 | -1322 | 106 | -1329 | -1126 |
| Cash From Investing Activities | -623 | -2344 | -37557 | 596 | -1006 |
| Capital Expenditures | -695 | -787 | -798 | -552 | -638 |
| Other Investing Cash Flow Items, Total | 72 | -1557 | -36759 | 1148 | -368 |
| Cash From Financing Activities | -24803 | -19039 | -11501 | 18708 | -14396 |
| Financing Cash Flow Items | -1102 | -674 | -333 | -552 | -104 |
| Total Cash Dividends Paid | -10043 | -9261 | -7716 | -6366 | -5580 |
| Issuance (Retirement) of Stock, Net | -1225 | -690 | -769 | -621 | -11941 |
| Issuance (Retirement) of Debt, Net | -12433 | -8414 | -2683 | 26247 | 3229 |
| Foreign Exchange Effects | -62 | -97 | -5 | 7 | -39 |
| Net Change in Cash | -545 | 1297 | -31475 | 32635 | -2014 |
| Deferred Taxes | -1931 | -898 | -2325 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 241 | 11845 | 9373 | 5421 | 4493 |
| Cash From Operating Activities | 4193 | 24943 | 17515 | 9913 | 4908 |
| Cash From Operating Activities | 179 | 778 | 582 | 401 | 198 |
| Amortization | 1948 | 7689 | 5728 | 3704 | 1855 |
| Deferred Taxes | -267 | -1931 | -1415 | -794 | -194 |
| Non-Cash Items | 2917 | 6820 | 4348 | 3620 | -169 |
| Changes in Working Capital | -825 | -258 | -1101 | -2439 | -1275 |
| Cash From Investing Activities | -499 | -623 | -175 | -1461 | -1591 |
| Capital Expenditures | -175 | -695 | -482 | -305 | -162 |
| Other Investing Cash Flow Items, Total | -324 | 72 | 307 | -1156 | -1429 |
| Cash From Financing Activities | -6192 | -24803 | -15169 | -9651 | -6972 |
| Financing Cash Flow Items | -290 | -1102 | -776 | -456 | -225 |
| Total Cash Dividends Paid | -2661 | -10043 | -7537 | -5033 | -2526 |
| Issuance (Retirement) of Stock, Net | -1890 | -1225 | -1274 | -1281 | -1342 |
| Foreign Exchange Effects | 8 | -62 | -85 | -26 | 7 |
| Net Change in Cash | -2490 | -545 | 2086 | -1225 | -3648 |
| Issuance (Retirement) of Debt, Net | -1351 | -12433 | -5582 | -2881 | -2879 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.9811 | 158520932 | -1102065 | 2023-06-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.1935 | 91667533 | 717450 | 2023-06-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.4295 | 78182567 | 1156130 | 2023-06-30 | LOW |
| Capital International Investors | Investment Advisor | 2.4448 | 43152741 | 404379 | 2023-06-30 | LOW |
| JP Morgan Asset Management | Investment Advisor | 2.2158 | 39109666 | -1259978 | 2023-06-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.9803 | 34952938 | 907917 | 2023-06-30 | LOW |
| Capital Research Global Investors | Investment Advisor | 1.8439 | 32545522 | -3168845 | 2023-06-30 | LOW |
| Charles Schwab Investment Management, Inc. | Investment Advisor | 1.2916 | 22797052 | 1260396 | 2023-06-30 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.0634 | 18769556 | 1466171 | 2022-12-31 | LOW |
| Morgan Stanley Smith Barney LLC | Investment Advisor | 1.0131 | 17881789 | -33713 | 2023-06-30 | LOW |
| Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 0.7532 | 13294516 | -686858 | 2023-06-30 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7155 | 12628445 | -487918 | 2023-06-30 | LOW |
| Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.7154 | 12627584 | 741031 | 2023-06-30 | LOW |
| BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.687 | 12125043 | 319918 | 2023-06-30 | LOW |
| BlackRock Asset Management Ireland Limited | Investment Advisor | 0.614 | 10837075 | 139722 | 2023-06-30 | LOW |
| Janus Henderson Investors | Investment Advisor/Hedge Fund | 0.6075 | 10723261 | -2772215 | 2023-06-30 | LOW |
| T. Rowe Price Associates, Inc. | Investment Advisor | 0.6039 | 10658843 | -4389662 | 2023-06-30 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 0.6019 | 10624630 | -1866636 | 2023-06-30 | LOW |
| UBS Financial Services, Inc. | Investment Advisor | 0.5741 | 10133661 | 244001 | 2023-06-30 | LOW |
| BofA Global Research (US) | Research Firm | 0.5574 | 9838032 | -2536190 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
AbbVie Company profile
AbbVie Inc. is a research-based pharmaceutical company, specialising in the discovery and development of biopharmaceuticals and small molecule drugs. With a team of around 29,000 scientists, researchers, manufacturing specialists and communications professionals across the globe, the company introduces new approaches to treating chronic conditions and life-threatening health issues. In 2019, AbbVie was ranked 96th on the Fortune 500 list of America’s biggest companies. More than 30 million patients in over 170 countries are treated by AbbVie’s medicines annually.
Headquartered in North Chicago, Illinois, AbbVie has 22 primary research and manufacturing facilities around the world. The company’s research centres are in the US, Germany and Japan; and its manufacturing sites are located in the USA, Puerto Rico, Ireland, Germany, Italy and Singapore.
The company produces medicines aimed at treating autoimmune diseases, cancers, viruses (including hepatitis C and HIV), neurological and metabolic disorders. According to the Wall Street Journal, in 2016, a specialty drug ibrutinib, retailed by the company, cost from $116,600 to $155,400 a year wholesale in the US. AbbVie estimates global sales of the drug at $5 billion in 2020.
The history of AbbVie started in 2013 when Abbott Laboratories split into two publicly traded companies. One, using the old company name, was to specialise in medical equipment and devices and nutritional products; the other, AbbVie, was to be a research-driven pharmaceutical manufacturer. From the start, AbbVie was interested in acquisitions: in 2014, it acquired ImmuVen for an undisclosed amount, and in 2015, AbbVie acquired oncology firm Pharmacyclics and its treatment for blood cancers.
Presently, the AbbVie share price is listed on the New York Stock Exchange (NYSE). It is also a constituent of both the S&P 100 and 500 indices. In 2018, AbbVie reported its annual revenues of over $32.75 billion. During the same year, the ABBV stock price hit an all-time high of $123. As of July 2019, the company’s market capitalisation was set at around $106.13 billion.
Get the latest news on the Abbvie share price and stay on top of the ABBV share price chart with Capital.com.
| Industry: | Pharmaceuticals (NEC) |
1 N Waukegan Rd
NORTH CHICAGO
ILLINOIS 60064
US
Income Statement
- Annual
- Quarterly
News
December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com